Suman Paul, MBBS, PhD

Medical Director, Cell Therapy Laboratory

Associate Professor of Oncology

Sidney Kimmel Comprehensive Cancer Center

• Researchers Create Modified Antibodies to Target RAS and p53 in Cancer, Cancer.gov (April 2, 2021)
• Mutant Gene-Targeted Immunotherapy Approach Developed, Brookhaven National Laboratory (April 2, 2021)
• Advances in Off-the-Shelf Immunotherapy: Expert Discussion, Oncology Times (October 5, 2021)
• First soluble TCR therapy opens ‘new universe’ of cancer targets. Nature Biotechnology (March 24, 2022)
• Leukemia Lymphoma Society award recipient, Leukemia & Lymphoma Society
• Johns Hopkins Investigators Develop Novel Treatment for T-cell Leukemias and Lymphoma, HopkinsMedicine.org (April 2, 2024)

Bispecific Antibody Therapy, CAR T Cell Therapy, T-cell Acute Lymphoblastic Leukemias, T-cell Lymphomas

Suman Paul Laboratory - Lab Website

• At the Suman Paul laboratory, we are focused on developing new antibodies and cell therapies for cancer treatment. Our team of researchers are dedicated to identifying novel targets, mechanisms for cancer therapy and developing innovative solutions to improve patient outcomes. We work closely with basic science researchers and clinicians to accelerate the translation of our discoveries into clinical practice.

https://www.ncbi.nlm.nih.gov/myncbi/suman.paul.1/bibliography/public/

• Paul S, ... Vogelstein B. TCR beta chain-directed bispecific antibodies for the treatment of T-cell cancer. Science Translational Medicine. 2021. PMID: 33649188
• Nichakawade T, ... Paul S. TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers. Nature 2024. PMID: 38538786
• Paul S, ... Zhou S. Cancer therapy with antibodies. Nature Reviews Cancer 2024. PMID 38740967
• Ge J, ... Paul S. TRBC2-targeting antibody-drug conjugates for the treatment of T-cell cancers. Nature Cancer 2025. PMID: 41429932
• Tabbara N, ... Paul S. Improved Overall Survival with Checkpoint Inhibition and Allogeneic Transplantation in Relapsed Hodgkin Lymphoma. Blood Advances 2025. PMID: 39693511

• TRBC1 and TRBC2 bispecific antibodies for targeting T-cell cancers, 63/150,232
• Methods and materials for treating t cell cancers, 63/119,753,

• Pre-doctoral Fellowship, American Heart Association, 2010
• American Association of Immunologists Young Investigator Award, 2012
• Val-G-Hemming Pre-doctoral Fellowship, Henry M Jackson Foundation, 2012
• Emma L Bockman Award, Outstanding Scholastic Achievement, Uniformed Services University, Bethesda, MD, 2013
• American College of Physicians Young Investigator Award, 2016
• Alpha Omega Alpha (AΩA) Resident Inductee, 2017
• MacMillan Scholar, Johns Hopkins University, Baltimore, MD, 2020
• SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship, 2020
• American Society of Hematology (ASH) Scholar Award, 2022
• Sir William Osler Young Investigator Award, Intercultural Clinical Club, 2023
• Director’s Teaching Award, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, 2024

• Society for Immunotherapy of Cancer
• American Society of Clinical Oncology
• American Society of Hematology